Flucloxacillin Sodium for Injection
Flucloxacillin sodium for injection is suitable for the treatment of the following infections caused by sensitive Gram-positive bacteria, including Staphylococcus and Streptococcus producing β - lactamases: 1. Skin and soft tissue infections, such as boils, pains, abscesses, cellulitis, pustulosis, infectious burns, skin graft protection, infectious skin conditions, such as ulcer, eczema and acne wound infection; 2 Respiratory tract infection: such as pneumonia, lung abscess, sinusitis, pharyngitis, tonsillitis, periscapular abscess, otitis media and external ear abscess; 3. Other infections: osteomyelitis, urethral infection, enteritis, meningitis, endocarditis, septicemia; 4. When appropriate, it is also recommended as a prophylactic for major surgical operations (such as cardiothoracic and orthopedic surgery).
Pharmacology: mechanism of action this product is a semi synthetic penicillin resistant enzyme. Its mechanism of action is similar to that of penicillin G. it binds to penicillin binding proteins (PBPs) on bacterial cell membrane, inhibits the biosynthesis of bacterial wall, causes the cell swelling, rupture and death, and plays a bactericidal role. This medicine is a germicide in breeding period. The antibacterial activity of this drug is characterized by good stability to penicillinase, strong bactericidal effect on penicillinase producing Staphylococcus aureus, but weaker than penicillin against penicillin sensitive Staphylococcus aureus and various Streptococcus. Antibacterial spectrum the drug has good antibacterial activity against penicillinase producing Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis. Enterococcus faecalis, methicillin resistant Staphylococcus aureus, intestinal negative bacilli, Pseudomonas aeruginosa, and Bacteroides fragilis were resistant to the drug.
Toxicology: the LDSN of flucloxacillin sodium orally was 3.88g/kg, and LD * of subcutaneous injection was 2.2g/kg. Rats were given flucloxacillin sodium 2005002000mg / kg, subcutaneous injection 250mg / kg, dogs oral 2005001000mg / kg, subcutaneous injection 250mg / kg for 25 weeks. There was no adverse reaction except slight stimulation at the subcutaneous injection site. In teratogenicity study, pregnant rats and mice were given flucloxacillin sodium 200 and 500 mg / kg. Results: there were no adverse reactions in maternal and fetal rats, but the incidence of early embryo death in high-dose group (far greater than the treatment dose) increased.
Audited Supplier 
){kind=link}